STOCK TITAN

roivw - ROIVW STOCK NEWS

Welcome to our dedicated page for roivw news (Ticker: roivw), a resource for investors and traders seeking the latest updates and insights on roivw stock.

Riovant Sciences Ltd. is a commercial-stage biopharmaceutical company focused on accelerating the development and commercialization of medicines that matter. The company's pipeline includes VTAMA®, a topical treatment for psoriasis and atopic dermatitis, IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor in autoimmune indications, and brepocitinib, a small molecule inhibitor for dermatomyositis and non-infectious uveitis. Through creating nimble subsidiaries, Roivant aims to advance its therapies and technologies, while also nurturing discovery-stage companies and health tech startups.

Rhea-AI Summary

Dermavant Sciences announced positive results from the Phase 3 PSOARING 3 long-term extension study for tapinarof cream 1% in treating plaque psoriasis. Over 52 weeks, tapinarof showed durable improvements in efficacy, quality of life, and tolerability without irritation. The study demonstrated significant enhancements in key metrics such as % body surface area (%BSA) affected and Psoriasis Area and Severity Index (PASI). Dermavant aims for FDA approval, with a target action date set for Q2 2022, which could position tapinarof as a novel therapeutic option for psoriasis patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
-
Rhea-AI Summary

Roivant Sciences (Nasdaq: ROIV) announced that CEO Matt Gline will present at Guggenheim’s Targeted Protein Degradation Day on March 16, 2022, at 1:15 p.m. ET. A live webcast will be accessible on the Roivant Investor Relations website. Roivant aims to enhance healthcare delivery by addressing inefficiencies and developing transformative medicines through its innovative Roivant platform. For updates, visit www.roivant.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.99%
Tags
conferences
-
Rhea-AI Summary

Genevant Sciences and Arbutus Biopharma have filed a lawsuit against Moderna for patent infringement related to key patents in nucleic acid delivery technology used in the manufacture of their COVID-19 vaccine, mRNA-1273. The patents involved include U.S. Patent Nos. 8,058,069, 8,492,359, and others. Importantly, Genevant and Arbutus are not seeking to halt the sale or distribution of mRNA-1273. The lawsuit follows a recent legal victory for Genevant and Arbutus, where a court upheld the patentability of their technologies.

Genevant emphasizes the significance of lipid nanoparticle technology in mRNA delivery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.41%
Tags
none
Rhea-AI Summary

Roivant Sciences has launched Hemavant, a subsidiary that secured a licensing agreement with Eisai Co., Ltd. for RVT-2001, targeting anemia in myelodysplastic syndromes. Dermavant is preparing for the anticipated FDA decision on tapinarof for psoriasis, with favorable Phase 3 trial results in atopic dermatitis. Genevant's patent portfolio was upheld against Moderna, and Immunovant aligned with the FDA for a pivotal trial in myasthenia gravis. As of December 31, 2021, Roivant reported $2.2 billion in cash, with a net loss of $306.1 million for the quarter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
-
Rhea-AI Summary

Roivant Sciences (NASDAQ: ROIV) will host a live conference call and webcast on February 14, 2022, at 8:00 a.m. ET to discuss its Q3 2021 financial results and provide a corporate update. The call can be accessed at +1-844-224-1923 for domestic and +1-214-989-7105 for international calls. Roivant will also present at three major healthcare conferences this February and March, including the SVB Leerink Global Healthcare Conference and Cowen Healthcare Conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
conferences earnings
-
Rhea-AI Summary

Roivant Sciences (Nasdaq: ROIV) announced CEO Matt Gline will present at two conferences: the B. Riley Securities Virtual Oncology Conference on January 27, 2022, at 12:30 p.m. ET, and the SVB Leerink Global Healthcare Conference on February 17, 2022, at 1:00 p.m. ET. Live webcasts will be available on the Roivant investor website, with archived recordings accessible for 30 days. Roivant aims to enhance healthcare delivery and develop transformative medicines through its innovative platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
conferences
Rhea-AI Summary

Roivant Sciences (Nasdaq: ROIV) announced a licensing agreement with Eisai Co., Ltd. for global rights to RVT-2001, aimed at treating transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (MDS). RVT-2001, an orally available small molecule, has been tested in over 80 human subjects. Roivant will expand its clinical trial for RVT-2001 this year. Details will be discussed during a presentation at the J.P. Morgan Healthcare Conference on January 10, 2022, at 2:15 p.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
conferences
-
Rhea-AI Summary

Roivant began trading on Nasdaq under the ticker ROIV and reported a cash balance of $2.5 billion. Dermavant presented positive results from its Phase 3 PSOARING 3 study of tapinarof for plaque psoriasis, highlighting that 58% of patients achieved a PGA score of 0 or 1 after long-term treatment. Aruvant shared encouraging data from its Phase 1/2 trial of ARU-1801 in sickle cell disease, with zero vaso-occlusive events observed for up to 18 months. Roivant's net loss was $225.6 million for the quarter, significantly up from $53.5 million year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.81%
Tags
-
Rhea-AI Summary

Roivant Sciences (Nasdaq: ROIV) has announced a quarterly investor call on November 15, 2021, at 8:00 a.m. ET to report its second quarter financial results. The company will also participate in the Jefferies London Healthcare Conference on November 17 and the Evercore ISI HealthCONx Conference on November 30. The call will be accessible via phone or webcast, with recordings available post-event. Roivant aims to enhance healthcare delivery by developing transformative medicines and technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.71%
Tags
conferences earnings
Rhea-AI Summary

Roivant Sciences has successfully completed its business combination with Montes Archimedes Acquisition Corp, leading to public trading on Nasdaq under the symbols ROIV and ROIVW. The deal, finalized on September 30, 2021, results in Roivant holding approximately $2.5 billion in cash. CEO Matt Gline highlighted this merger as an opportunity to enhance value for patients and shareholders. In a strategic move, Richard Pulik has been appointed as Chief Financial Officer, bringing over 20 years of industry expertise.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags

FAQ

What is Roivant Sciences Ltd. focused on?

Roivant Sciences Ltd. is focused on accelerating the development and commercialization of medicines that matter, with a pipeline of innovative treatments for various conditions.

What are some products in Roivant Sciences Ltd.'s pipeline?

Roivant Sciences Ltd.'s pipeline includes VTAMA®, IMVT-1402, batoclimab, and brepocitinib, targeting autoimmune diseases and other conditions.

How does Roivant Sciences Ltd. advance its pipeline?

Roivant Sciences Ltd. advances its pipeline by creating nimble subsidiaries or 'Vants' to develop and commercialize its medicines and technologies.

What additional initiatives does Roivant Sciences Ltd. undertake?

In addition to therapeutics, Roivant Sciences Ltd. incubates discovery-stage companies and health technology startups that complement its biopharmaceutical business.

What is the significance of Roivant Sciences Ltd.'s latest achievements?

Roivant Sciences Ltd. has recently achieved positive results in Phase 2 studies, such as the NEPTUNE study, showing the efficacy of brepocitinib in non-anterior non-infectious uveitis, indicating potential transformative benefits for patients.

roivw

Nasdaq:ROIVW

ROIVW Rankings

ROIVW Stock Data